Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes

Mari Björkman (Corresponding Author), Juha K. Rantala, Matthias Nees, Olli Kallioniemi

Research output: Contribution to journalArticleScientificpeer-review

4 Citations (Scopus)

Abstract

Alterations in epigenetic processes probably underlie most human malignancies. Novel genome-wide techniques, such as chromatin immunoprecipitation and high-throughput sequencing, have become state-of-the-art methods to map the epigenomic landscape of development and disease, such as in cancers. Despite these advances, the functional significance of epigenetic enzymes in cancer progression, such as prostate cancer, remain incompletely understood. A comprehensive mapping and functional understanding of the cancer epigenome will hopefully help to facilitate development of novel cancer therapy targets and improve future diagnostics. The authors have developed a novel cell microarray-based high-content siRNA screening technique suitable to address the putative functional role and impact of all known putative and novel epigenetic enzymes in cancer, including prostate cancer.
Original languageEnglish
Pages (from-to)683-689
JournalEpigenomics
Volume2
Issue number5
DOIs
Publication statusPublished - 2010
MoE publication typeA1 Journal article-refereed

Fingerprint

RNA Interference
Epigenomics
Prostatic Neoplasms
Enzymes
Pharmaceutical Preparations
Neoplasms
Genetic Epigenesis
Chromatin Immunoprecipitation
Small Interfering RNA
Genome
Therapeutics

Keywords

  • cell microarray technology
  • epigenetics
  • high-throughput screening
  • HTS
  • PrCa
  • prostate cancer
  • siRNA

Cite this

Björkman, Mari ; Rantala, Juha K. ; Nees, Matthias ; Kallioniemi, Olli. / Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. In: Epigenomics. 2010 ; Vol. 2, No. 5. pp. 683-689.
@article{94e773e71ec340f5a6b3445c10772a2b,
title = "Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes",
abstract = "Alterations in epigenetic processes probably underlie most human malignancies. Novel genome-wide techniques, such as chromatin immunoprecipitation and high-throughput sequencing, have become state-of-the-art methods to map the epigenomic landscape of development and disease, such as in cancers. Despite these advances, the functional significance of epigenetic enzymes in cancer progression, such as prostate cancer, remain incompletely understood. A comprehensive mapping and functional understanding of the cancer epigenome will hopefully help to facilitate development of novel cancer therapy targets and improve future diagnostics. The authors have developed a novel cell microarray-based high-content siRNA screening technique suitable to address the putative functional role and impact of all known putative and novel epigenetic enzymes in cancer, including prostate cancer.",
keywords = "cell microarray technology, epigenetics, high-throughput screening, HTS, PrCa, prostate cancer, siRNA",
author = "Mari Bj{\"o}rkman and Rantala, {Juha K.} and Matthias Nees and Olli Kallioniemi",
year = "2010",
doi = "10.2217/epi.10.48",
language = "English",
volume = "2",
pages = "683--689",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "5",

}

Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. / Björkman, Mari (Corresponding Author); Rantala, Juha K.; Nees, Matthias; Kallioniemi, Olli.

In: Epigenomics, Vol. 2, No. 5, 2010, p. 683-689.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes

AU - Björkman, Mari

AU - Rantala, Juha K.

AU - Nees, Matthias

AU - Kallioniemi, Olli

PY - 2010

Y1 - 2010

N2 - Alterations in epigenetic processes probably underlie most human malignancies. Novel genome-wide techniques, such as chromatin immunoprecipitation and high-throughput sequencing, have become state-of-the-art methods to map the epigenomic landscape of development and disease, such as in cancers. Despite these advances, the functional significance of epigenetic enzymes in cancer progression, such as prostate cancer, remain incompletely understood. A comprehensive mapping and functional understanding of the cancer epigenome will hopefully help to facilitate development of novel cancer therapy targets and improve future diagnostics. The authors have developed a novel cell microarray-based high-content siRNA screening technique suitable to address the putative functional role and impact of all known putative and novel epigenetic enzymes in cancer, including prostate cancer.

AB - Alterations in epigenetic processes probably underlie most human malignancies. Novel genome-wide techniques, such as chromatin immunoprecipitation and high-throughput sequencing, have become state-of-the-art methods to map the epigenomic landscape of development and disease, such as in cancers. Despite these advances, the functional significance of epigenetic enzymes in cancer progression, such as prostate cancer, remain incompletely understood. A comprehensive mapping and functional understanding of the cancer epigenome will hopefully help to facilitate development of novel cancer therapy targets and improve future diagnostics. The authors have developed a novel cell microarray-based high-content siRNA screening technique suitable to address the putative functional role and impact of all known putative and novel epigenetic enzymes in cancer, including prostate cancer.

KW - cell microarray technology

KW - epigenetics

KW - high-throughput screening

KW - HTS

KW - PrCa

KW - prostate cancer

KW - siRNA

U2 - 10.2217/epi.10.48

DO - 10.2217/epi.10.48

M3 - Article

VL - 2

SP - 683

EP - 689

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 5

ER -